Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation
NCT04959175Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by National Cancer Institute. Started Sep 2021; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04959175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959175.